Feb 26, 2020
Well not really Stem Cells, but certainly Platelet Rich Plasma and Growth Factor Protein Concentrate. Knowing that the term Stem Cells attracts attention, I used it here so hopefully, you would read this Blog.
On Saturday, February 15, I departed for a week of skiing in Vail, Colorado. In anticipation of the sojourn, in Late December, I underwent an intervention into both of my hips and knees using Platelet Rich plasma derived Proteins termed Growth Factors. My last Blog explored The Recreational Impact of Biologics: Stem cells, Growth Factors and Platelet Rich Plasma. While I dedicate about 5 to 6 hours a week in pursuit of conditioning; two weeks ago, I returned to spin class at the gym after a five-year hiatus substituting the demands of one-hour spin class for the stationary bicycle. While the late December interventions provided pain relief in my hips and knees, I didn’t feel that I would stand up to the demands of Vail, even with my customary rowing ergometer and strength training routines. It took several classes but here I am in Vail returning to the thrilling days of yester-year on spectacular powder and runs.
Returning to the office this morning, it was time to sit down and finish writing this blog. My first act, en route, was to pick up a copy of the February 24, edition of Crain’s Chicago Business, anticipating the appearance of A ROUNDTABLE DISCUSSION ORTHOPEDIC MEDICINE. I had been selected as one of four Orthopedic Surgeons taking part in a question and answer platform. You may find the article quite informative and find it at CHICAGOBUSINESS.COM or find Crain’s Chicago Business wherever you purchase the daily newspaper. One particular question and answer is worth repeating. In response to the question “What new technologies and surgical techniques are you using?”; I responded “Biologics is the new technology that I use with a needle rather than a knife.” A second question and answer are worth repeating. “What insurance issues and concerns are common with orthopedic treatment?” “Recognizing the financial burdens imposed by some of my advanced technology offerings, I’ve created several affordable care alternatives.” Here is the link to the entire article: https://www.chicagobusiness.com/crains-custom-media/roundtable-discussions.
Now comes the readers’ choice. You may read the entire article by buying a newspaper; click the highlighted above; visit my web site at www.sheinkopmd.com or call and schedule a consultation (312) 475-1893.
Download Full Article Here
Tags: biologics, growth factors protein concentrate, regenerative medicine, stem cell intervention
May 14, 2018
“Mitch, not sure if you heard, but the FDA via the DOJ has requested injunctions against the mothership clinics of Berman and Lander, as well as the US Stem Cell clinic run by Comella. We can hope that criminal indictments might follow, since they certainly are some of the most flagrant violators of the law in recent med I can think of. The SCIA group can’t be too far behind. It seems that advertising all kinds of cures for everything that ails the patient makes you a higher priority target.” (Personal communication)
I am dedicated to providing patients with the best possible care in regenerative medicine and am pleased to announce that I have adopted a technology platform developed by Greyledge Technologies (Vail, CO). Their technology to generate platelet-rich plasma (PRP) and bone marrow-derived cell concentrate (BMC) is derived from successfully operating a laboratory that is registered with the FDA (listed as a “component preparation and collection facility”, FEI 3008724474), which has cleared two audits with no issues. Based on their platform, I offer my patients customized therapy, since each preparation is analyzed for platelets, red blood cells and white blood cells (among 23 parameters), which I review prior to treatment. This knowledge permits me to make adjustments based on my more than 40 years of experience in orthopedic surgical and now cellular orthopedic practice. No other system or technology gives me this kind of capability to personalize your treatment.
As a result of the technology I have adopted, my office has been able to create a scientific outcomes data base using the same parameters in cellular orthopedics as when I was the director at one of the five largest joint replacement programs in the country. At that time, I pioneered the integration of patient are with research and education. The latter allowed me to rise to the position of full professor; having publish over 75 scientific articles in the field of hip and knee joint replacement. I am happy to update you with the fact that I am at it again. On June 10, my paper concerning the preliminary outcomes of combined intraarticular and intraosseous stem cell intervention for knee arthritis will be presented in Las Vegas at of The Orthopedic and Biologic Institute (TOBI) annual meeting. The manuscript concerning Autologous Bone Marrow Concentrate and Platelet Product for Symptomatic Knee Arthritis: A Randomized Controlled Trial, Minimum 2 Year Follow-Up was submitted to a major orthopedic journal and is one of three papers I have been invited to deliver from the scientific podium of The Medrebels, October 26 to 28 meeting in Austin, Texas.
If you want to avail yourself of the best opportunity to postpone, perhaps avoid a joint replacement for arthritis while enjoying pain relief and restoration of an active life style, chose science over advertised anecdote. Call (312) 475-1893 to schedule an appointment. You may access my website and watch the webinar at www.Ilcellulartherapy.com.
Tags: APGC injection, arthritis, BMC injection, Bone Marrow Concentrate, bone on bone, Greyledge, Growth Factor Concentrate, Hip pain, intraarticular, intraosseous, joint pain, knee pain, Medrebels, Osteoarthritis, PRP, stem cell intervention, TOBI
